200 related articles for article (PubMed ID: 37982738)
1. A PERK-Specific Inhibitor Blocks Metastatic Progression by Limiting Integrated Stress Response-Dependent Survival of Quiescent Cancer Cells.
Calvo V; Zheng W; Adam-Artigues A; Staschke KA; Huang X; Cheung JF; Nobre AR; Fujisawa S; Liu D; Fumagalli M; Surguladze D; Stokes ME; Nowacek A; Mulvihill M; Farias EF; Aguirre-Ghiso JA
Clin Cancer Res; 2023 Dec; 29(24):5155-5172. PubMed ID: 37982738
[TBL] [Abstract][Full Text] [Related]
2. Dual function of pancreatic endoplasmic reticulum kinase in tumor cell growth arrest and survival.
Ranganathan AC; Ojha S; Kourtidis A; Conklin DS; Aguirre-Ghiso JA
Cancer Res; 2008 May; 68(9):3260-8. PubMed ID: 18451152
[TBL] [Abstract][Full Text] [Related]
3. Defining the transcriptional and biological response to CDK4/6 inhibition in relation to ER+/HER2- breast cancer.
Knudsen ES; Witkiewicz AK
Oncotarget; 2016 Oct; 7(43):69111-69123. PubMed ID: 27564114
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of metastatic outgrowth from single dormant tumor cells by targeting the cytoskeleton.
Barkan D; Kleinman H; Simmons JL; Asmussen H; Kamaraju AK; Hoenorhoff MJ; Liu ZY; Costes SV; Cho EH; Lockett S; Khanna C; Chambers AF; Green JE
Cancer Res; 2008 Aug; 68(15):6241-50. PubMed ID: 18676848
[TBL] [Abstract][Full Text] [Related]
5. De-differentiation confers multidrug resistance via noncanonical PERK-Nrf2 signaling.
Del Vecchio CA; Feng Y; Sokol ES; Tillman EJ; Sanduja S; Reinhardt F; Gupta PB
PLoS Biol; 2014 Sep; 12(9):e1001945. PubMed ID: 25203443
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant neratinib promotes ferroptosis and inhibits brain metastasis in a novel syngeneic model of spontaneous HER2
Nagpal A; Redvers RP; Ling X; Ayton S; Fuentes M; Tavancheh E; Diala I; Lalani A; Loi S; David S; Anderson RL; Smith Y; Merino D; Denoyer D; Pouliot N
Breast Cancer Res; 2019 Aug; 21(1):94. PubMed ID: 31409375
[TBL] [Abstract][Full Text] [Related]
7. Prodigiosin activates endoplasmic reticulum stress cell death pathway in human breast carcinoma cell lines.
Pan MY; Shen YC; Lu CH; Yang SY; Ho TF; Peng YT; Chang CC
Toxicol Appl Pharmacol; 2012 Dec; 265(3):325-34. PubMed ID: 22982536
[TBL] [Abstract][Full Text] [Related]
8. PERK activation by CCT020312 chemosensitizes colorectal cancer through inducing apoptosis regulated by ER stress.
Lei Y; He L; Yan C; Wang Y; Lv G
Biochem Biophys Res Commun; 2021 Jun; 557():316-322. PubMed ID: 33894420
[TBL] [Abstract][Full Text] [Related]
9. Lineage commitment pathways epigenetically oppose oncogenic Gαq/11-YAP signaling in dormant disseminated uveal melanoma.
Kadamb R; Anton ML; Purwin TJ; Chua V; Seeneevassen L; Teh J; Angela Nieto M; Sato T; Terai M; Roman SR; De Koning L; Zheng D; Aplin AE; Aguirre-Ghiso J
bioRxiv; 2024 Mar; ():. PubMed ID: 38496663
[TBL] [Abstract][Full Text] [Related]
10. Atiprimod triggered apoptotic cell death via acting on PERK/eIF2α/ATF4/CHOP and STAT3/NF-ΚB axis in MDA-MB-231 and MDA-MB-468 breast cancer cells.
Coker-Gurkan A; Can E; Sahin S; Obakan-Yerlikaya P; Arisan ED
Mol Biol Rep; 2021 Jun; 48(6):5233-5247. PubMed ID: 34244887
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of proliferation by PERK regulates mammary acinar morphogenesis and tumor formation.
Sequeira SJ; Ranganathan AC; Adam AP; Iglesias BV; Farias EF; Aguirre-Ghiso JA
PLoS One; 2007 Jul; 2(7):e615. PubMed ID: 17637831
[TBL] [Abstract][Full Text] [Related]
12. Dual role of the integrated stress response in medulloblastoma tumorigenesis.
Stone S; Ho Y; Li X; Jamison S; Harding HP; Ron D; Lin W
Oncotarget; 2016 Sep; 7(39):64124-64135. PubMed ID: 27802424
[TBL] [Abstract][Full Text] [Related]
13. Use of Small-molecule Inhibitory Compound of PERK-dependent Signaling Pathway as a Promising Target-based Therapy for Colorectal Cancer.
Rozpędek W; Pytel D; Wawrzynkiewicz A; Siwecka N; Dziki A; Dziki Ł; Diehl JA; Majsterek I
Curr Cancer Drug Targets; 2020; 20(3):223-238. PubMed ID: 31906838
[TBL] [Abstract][Full Text] [Related]
14. How much do we know about the metastatic process?
Rodriguez-Tirado C; Sosa MS
Clin Exp Metastasis; 2024 Mar; ():. PubMed ID: 38520475
[TBL] [Abstract][Full Text] [Related]
15. An in vitro system to study tumor dormancy and the switch to metastatic growth.
Barkan D; Green JE
J Vis Exp; 2011 Aug; (54):. PubMed ID: 21860375
[TBL] [Abstract][Full Text] [Related]
16. Visualization of endogenous p27 and Ki67 reveals the importance of a c-Myc-driven metabolic switch in promoting survival of quiescent cancer cells.
La T; Chen S; Guo T; Zhao XH; Teng L; Li D; Carnell M; Zhang YY; Feng YC; Cole N; Brown AC; Zhang D; Dong Q; Wang JY; Cao H; Liu T; Thorne RF; Shao FM; Zhang XD; Jin L
Theranostics; 2021; 11(19):9605-9622. PubMed ID: 34646389
[No Abstract] [Full Text] [Related]
17. Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells.
Wang X; Wong J; Sevinsky CJ; Kokabee L; Khan F; Sun Y; Conklin DS
Mol Cancer Ther; 2016 Sep; 15(9):2198-208. PubMed ID: 27256378
[TBL] [Abstract][Full Text] [Related]
18. PERK promotes cancer cell proliferation and tumor growth by limiting oxidative DNA damage.
Bobrovnikova-Marjon E; Grigoriadou C; Pytel D; Zhang F; Ye J; Koumenis C; Cavener D; Diehl JA
Oncogene; 2010 Jul; 29(27):3881-95. PubMed ID: 20453876
[TBL] [Abstract][Full Text] [Related]
19. Synergistic anti-cancer activity of CDK4/6 inhibitor palbociclib and dual mTOR kinase inhibitor MLN0128 in pRb-expressing ER-negative breast cancer.
Yamamoto T; Kanaya N; Somlo G; Chen S
Breast Cancer Res Treat; 2019 Apr; 174(3):615-625. PubMed ID: 30607633
[TBL] [Abstract][Full Text] [Related]
20. Targeting disseminated estrogen-receptor-positive breast cancer cells in bone marrow.
Buschhaus JM; Humphries BA; Eckley SS; Robison TH; Cutter AC; Rajendran S; Haley HR; Bevoor AS; Luker KE; Luker GD
Oncogene; 2020 Aug; 39(34):5649-5662. PubMed ID: 32678295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
